


# Beyond skin deep: Transforming patient care through Research and Development of non-invasive, in-vivo bedside skin imaging tools



**Adj Prof Steven Thng**  
Executive Director, Skin Research Institute of Singapore  
Senior Consultant, National Skin Centre



Research collaboration/funding

Galderma

Johnson and Johnson

Loreal

iTHERA

Clinuvel

P&G

ASLAN Pharma

LVMH

JW Pharma

Pola

# Disclosures

No conflict of interest for this talk





Why Skin Imaging in dermatology?









What is this lesion?





# Dermatology as it is “today”





# Dermatology as it is “today”

## Some considerations of skin biopsy

- Psychological stress

- Sampling error




- Scarring

- Repeated biopsy needed for follow up

- Biopsy cannot be done at the same site!



# Main Skin Imaging Tools in 2010

Imaging Tool	Advantages	Disadvantages
<b>Reflectance confocal microscopy (RCM)</b> 	<ul style="list-style-type: none"> <li>High cellular resolution (5-10 <math>\mu\text{m}</math>)</li> <li>Tissue morphology</li> </ul>	<ul style="list-style-type: none"> <li>Limited penetration depth (150-200 <math>\mu\text{m}</math>)</li> <li>2D imaging</li> </ul>
<b>HD Optical coherence tomography (OCT)</b> 	<ul style="list-style-type: none"> <li>High cellular resolution (10-30 <math>\mu\text{m}</math>)</li> <li>Tissue morphology</li> <li>3D imaging</li> </ul>	<ul style="list-style-type: none"> <li>Limited penetration depth (1-3 mm)</li> </ul>
<b>Ultrasound</b> 	<ul style="list-style-type: none"> <li>Good spatial resolution (100-200 <math>\mu\text{m}</math>)</li> <li>High penetration depth of up to a few cm</li> <li>Tissue morphology; blood flow (Doppler)</li> <li>3D imaging</li> </ul>	<ul style="list-style-type: none"> <li>Inability to differentiate hypoechoic tumor, inflammation or fat</li> </ul>











# The In-Vivo Confocal





















# THE BEAUTY OF THE CONFOCALS





# Structural Imaging for Cancer






# Skin Cancer

- In-vivo confocal
  - Resolution of 1-5 micrometer
  - Visualize cellular level
  - Depth of up to 300 micrometer
- Diagnosis of BCC
  - Sensitivity of 91.3%
  - Specificity of 97%

Milind et al Lasers Surg Med 2017





# Addressing Confocal Diagnostic Accuracy

Prospective clinical-pathological-Imaging study 2011 to 2012

- 415 lesions imaged
  - 91 cases of malignancies
    - 82 cases of BCC
    - 8 cases of SCC
    - 1 case of melanoma
- Confocal Criteria for diagnosis of BCC:-
  - Tumor nests
  - Peripheral palisading
  - Vascularity
  - Clefting
  - *Loss of honeycomb pattern and pleomorphism of overlying epidermis*
- Increase specificity and decrease sensitivity
  - Employ top 4 criteria for confirmed diagnosis
  - Less than 4 criteria, biopsy.



# Validation study of confocal imaging for BCC

- A total of 1031 cases enrolled
  - 1132 lesions imaged
    - 252 cases of malignancies
      - 223 cases of BCC
      - 21 cases of SCC
      - 8 case of melanoma

Confocal		Literature	Biopsy	
Sensitivity	98.8% (CI 93-99)	91%	Sensitivity	96.43% (CI 89-99)
Specificity	97.9% (CI 86-99%)	97%	Specificity	100%
PPV	98.55%		PPV	100%
NPV	98.67%		NPV	97%

# PREVIOUS SKIN CANCER WORKFLOW



Clinical  
Diagnosis

2 weeks  
Biopsy  
Result

2-3 weeks  
Final  
excision



# Fast, painless way of detecting skin cancer

Linette Lai Political Correspondent 

Getting tested for skin cancer used to mean a painful biopsy, followed by a long, anxious wait for the results.

But doctors at the National Skin Centre (NSC) are now able to tell if someone has the disease simply by looking at his skin through a special machine.

Unlike a biopsy, no stitches are needed and a diagnosis can be made in as little as five minutes.

## ST VIDEOS




British family whose daughter died in Negeri Sembilan files civil suit against resort operator



Spirited away: Carlos Ghosn's brazen disappearing act leaves questions unanswered

- Cost savings of \$800,000 annually

















# What's next?

Current limitations of confocal service

- Performed by specially trained dermatologist
  - Costly and confined to certain days of the week

Ideal state:-

- Confocal performed by technician
  - Use of AI for diagnosis
  - Enable technology to be deployed across centres in Singapore and worldwide
  - Funded by NMRC Feb 2020-2023



Pellacani@Modena






Adams@NTU SCSE



# Pushing the boundaries

From 2D to 3D reconstruction.

- Current surgical techniques is by **surgical margins** based on type of cancer, aggressiveness and site of cancer




# Pushing the boundaries

From 2D to 3D reconstruction.

- Current surgical techniques is by **surgical margins** based on type of cancer, aggressiveness and site of cancer
- MOHs Surgery
  - Not available in all centres
  - Time consuming, costly.

*Moh's micrographic surgery (MMS)*





# Pushing the boundaries

From 2D to 3D reconstruction.


- Current surgical techniques is by surgical mapping, which takes into account type of cancer, aggressiveness and site of cancer

- MOHs Surgery





- Not available in all centres
- Time consuming, costly

Pre-operative mapping to determine functional and physical structure of NMSC


*Moh's micrographic surgery (MMS)*



# Photoacoustic (PA) Imaging Principle




Multispectral  
Unmixing






# Multiple Endogenous Contrast



Absorption profiles of skin chromophores (Hb: deoxy-haemoglobin; HbO<sub>2</sub>: oxy-haemoglobin)



Multispectral MSOT images can resolve various skin chromophores




# Developing Image Delineation Algorithm






# Refining the mapping of BCC in-vivo

- Study done in 2016<sup>1</sup>
- 21 patients enrolled
  - Using a composite of hemoglobin and melanin signals endogenously
  - Map out the dimensions of the tumor, compared with histology dimensions
  - Composite signals adjusted till correlation of more than 0.8 for length, breadth and depth.



1. ABE Attia, Thng et al. Photoacoustics 2017

# Mapping a pigmented BCC using a 3D probe






# **Validation Study and Results**

# Study Design

- Study Design:-
  - Prospective, clinic-pathological and imaging correlation study.
  - Patients with BCC scheduled for excision were imaged with MSOT and dimensions determined
  - Dimensions compared with histopathological measurements
- Statistical analysis
  - GraphPad Prism 6 software (GraphPad Software, San Diego CA)
  - Pearson's correlation coefficient, intraclass coefficient of correlation, and Bland-Altman method with 95% limits of agreement were employed to compare between tumor dimensions calculated by histology and vMSOT.







# Results


- Study Population
  - 26 patients recruited
    - 6 cases were excluded as size if beyond the FOV of MSOT
    - 12 cases were female and 8 cases male
    - Site
      - 16 on face, 3 on trunk, 1 on limbs

# Results 1:- Correlation analysis




# Results 1:- Correlation analysis (Bland-Altman plots)

Difference vs. average: Correlation of tumor depth



Average difference of about 0.5 to 1 mm


Difference vs. average: Correlation of tumor length



Average difference of about 1mm - 2mm




# Case examples



# Imaging Across different Fitzpatrick skin phototypes


**Fitzpatrick Type II**



- Erythematous plaque

Dimension	MSOT	Histology
Depth (mm)	2.48	2.70
Length (mm)	4.22	5.20
Width (mm)	3.60	

**Fitzpatrick Type IV**



- Pigmented plaque

Dimension	MSOT	Histology
Depth (mm)	2.32	2.10
Length (mm)	7.56	7.50
Width (mm)	4.32	

# Discussion

- First in vivo clinical use of MSOT for 3D mapping and visualization of BCC through a composite of melanin and vascular signals.
- Real time, non-invasive, label-free, deep penetration
- MSOT measurements of lesion dimensions correlated well with histology
- Accuracy is better
  - In pigmented BCCs versus non-pigmented BCCs.
  - Tumor depth has better correlation than tumor length
- MSOT is not accurate in very superficial BCC less than 0.5mm.
  - Unisotropic resolution at the peripheral regions of the FOV of the matrix array vMSOT detector. The lower detection limit of the vMSOT may lie between 0.47 and 1.28 mm.
- MSOT seems to be able to map BCCs accurately with margin of error of up to 0.5 mm (in depth) and 1.2mm (in length)
- Possible to be employed as pre-MOHs to reduce number of stages in MOHs.




# Future plans




## Multispectral Optoacoustic Tomography (MSOT)

## Raster-scan Optoacoustic Mesoscopy (RSOM)

**Clinical MSOT Experimental Imaging Platform (EIP)**



**2D probe 3D probe**




**Clinical RSOM**

Imaging modality	MSOT	RSOM
Spatial resolution ( $\mu\text{m}$ )	$\sim 80$	$\sim 30$
Penetration depth (mm)	10	2-3
Field-of-view (xyz, mm)	$10 \times 10 \times 12$	$3 \times 5 \times 3$
Label Free Imaging	Yes	Yes
Information derived	<ul style="list-style-type: none"> <li>Anatomical</li> <li>Functional</li> <li>Molecular</li> </ul>	<ul style="list-style-type: none"> <li>Anatomical</li> <li>Functional (for multi-wavelength)</li> </ul>

NMRC funded research 2020-2023.

# Structural Imaging for **Skin Inflammatory Disorders** – Vitiligo Stability



# Vitiligo Grafting.

In National Skin Centre over the last 5 years



## Segmental Vitiligo

- Different pathogenesis from Vitiligo Vulgaris.
- Rapidly progressing phase, then stabilize

## Complete to Excellent Repigmentation

95% of cases over the last 5 years



## Partial Repigmentation

All cases had partial repigmentation and usually more than 50% repigmentation.



## Vitiligo Vulgaris

- Auto-immune pathogenesis
- Waxes and wanes
- Stability is important



## Complete to Excellent Repigmentation


70% over the last 5 years

## None Responders

- About 10% do not respond
- Some developed active vitiligo 3-6 months post grafting



To graft or nor to graft...that is the question



## Vitiligo Vulgaris

Selection of patients is of utmost importance!



**Failure of conventional treatment**

No significant repigmentation after 9 months of treatment.



**Stable vitiligo**

No new or expanding lesions in the preceding 12 months



**Absence of koebner phenomena**

Scars are not hypo/depigmented



**No history of keloidal tendencies**

Relative contra-indication



**Positive test graft**

Mainly for patients with vitiligo vulgaris



# How do we better predict stability?



# Prediction of Stability



## Clinical Stability

Based on history and physical examination, range from 4 months to 3 years



## Biochemical Parameters

Serum anti-oxidant status, homovanillic acid (HVA) and vanillylmandelic acid




## Serological Studies

Presence and titres of auto-antibodies to tyrosine hydroxylase, TRP1,2



## Microscopic Studies

Peri-lesional skin looking for inflammatory cells, vacuolar changes in basal cells as well as degenerating melanocytes





# Can Confocal be used to define Stability?



What can confocal tell us about vitiligo?

# RCM and Prediction of Stability

Li et al. Indian Journal of Dermatology 2013



## Study Design

- 125 patients recruited
- RCM performed at lesional, perilesional and normal skin
- VIDA score to assess stability as compared to RCM score
- RCM-Histo correlation in active vitiligo group



## RCM Score

- Pigmentation status in the lesional skin:
- Status of the border of vitiligo lesion:
- Inflammatory cell infiltration:
- Melanocyte regeneration


Total RCM score:

- $<1$  represented stable stage;
- $\geq 1$  represented active stage;
- $\geq 2$  represented rapid active stage


Group	VIDA (patients)	RCM (patients)
Rapid active stage group	30	26
Slow active stage group	40	37
Stable stage group	55	62

# RCM and Prediction of Stability

Li et al. Indian Journal of Dermatology 2013



Cases when RCM revealed inflammatory cells



Cases when RCM revealed NO inflammatory cells





# **Can RCM Predict Response to Grafting?**



# RCM and Prediction of Response to Grafting

SY Chuah, TG Thng. Skin Research and Technology 2018\*




## Study Design

- Prospective study
- Patients with vitiligo vulgaris scheduled for grafting imaged with RCM
- Compare RCM scores with VIDA scores and with response to grafting
- Positive response defines by more than 75% repigmentation.



## Assessments

- RCM score
  - Done by 2 dermatologists independently
- VIDA scores done independently of RCM score.
- Response to repigmentation assessed by 2 dermatologists




## Results

- 28 patients were enrolled over 1 year
  - 23 were included in assessment
  - 5 loss to follow up

# RCM and Prediction of Response to Grafting



SY Chuah, TG Thng. Skin Research and Technology 2018





# RCM and Prediction of Response to Grafting

SY Chuah, TG Thng. Skin Research and Technology 2018



# RCM and Prediction of Response to Grafting

SY Chuah, TG Thng. Skin Research and Technology 2018

## Predicting poor response to grafts:-

- VIDA has a very poor predictive value for failure of grafts
  - All 7 cases that failed has a VIDA score of 0. (Stable)
- RCM has excellent predictive value for failure of grafts
  - 6 out of 7 cases that failed has a RCM score of 1 and above.
  - 1 case of graft failure despite RCM score of 0. Could it be due to procedure?


## Predicting positive response to grafting

- RCM Score
  - For all cases scored by RCM to be stable, all achieved positive response to grafting
  - There were 6 cases that has features of active vitiligo on RCM but responded to grafting too\*.

Overall RCM score for predicting response to surgery is good.


- If RCM score is stable, all patients will achieve good repigmentation outcomes
- If RCM score is more than 0 (indicates active vitiligo), likelihood of failure of grafts is 50%.

# Structural Imaging for **Skin Inflammatory Disorders** – Atopic Dermatitis








## RSOM and AD




### RSOM Eczema Four calculated metrics




# RSOM and AD



(a) Mean Epidermis Thickness




(b) Total Blood Volume



(c) Mean Vessel Diameter





## Skin Composition Imaging

Skin Structural Imaging

Skin Chemical Composition Imaging

Image Analysis and AI



# Why the need for Skin Composition Imaging?

- Both skin structure and composition determines function of skin
- Structure is intact but functionally deficient
  - Atopic Dermatitis
    - Functional Barrier defect
    - Decreased expression of filaggrin
    - Downstream reduction in natural moisturising factors of the skin.
    - Current way to measure barrier defect is via trans-epidermal water loss (TEWL).

**Can we measure the chemical composition of skin by the bedside to better understand/correlate composition with function and disease?**

# Skin Chemical Composition Imaging


## HelioDerma for skin characterization



*Latest prototype*

Skin-related biomarkers		
collagen	melanin	ceramide
elastin	triolein	cholesterol
keratin	urea	water
.....	.....	.....

*Raman spectral database*




### Competitive advantages


- ❑ Handheld for inaccessible regions
- ❑ Confocal for depth profiling
- ❑ Comparable sensitivity with benchtop systems
- ❑ Integrated Raman spectral database
- ❑ Advanced spectral unmixing algorithms for biomarker quantification

*Fiber-based handheld confocal Raman spectroscopy system – Priority art filed (2017)*

# Raman Spectrum with Fitting and Functional Groups



## Skin Components Boxplots





The background of the slide features a dark blue space scene. On the left, a portion of the Earth is visible, showing clouds and landmasses. Overlaid on the entire scene is a complex, glowing blue network of interconnected lines and dots, resembling a global communication or data network. The network is denser on the left and more sparse on the right.

**So, where do we go from here.....**  
**Leveraging on our strengths**

# Integrating Different Components to Develop Disruptive Technologies

## SENSOR SYSTEMS

- Surface sensors
- Biomarkers
- Environmental sensors.



## STRUCTURAL IMAGING SYSTEMS

- 2D and 3D systems
- POC devices.




## CHEMICAL COMPOSITION IMAGING SYSTEMS

- Reducing footprint and cost
- Consumer care systems



## IMAGE ANALYSIS AND AI

- Diagnostics
- Quantifications
- Prognostics



## APPS AND DATA MANAGEMENT

- Suite of capabilities and not one disease systems
- Database management




DISEASES

HEALTH




# Hyper-personalised Monitoring Platforms for Health, Injury, and Disease

Vision: Skin as a “Window on Health”





# Vision: Skin as a “Window on Health”



## COMMUNITY HEALTHCARE

Polyclinics, GPs, Pharmacies


### Pharmacy diagnosis booths

- Surface sensors
- Surface imaging
- AI for automated diagnosis and dispensing of medication



### Polyclinic diagnosis systems

- Surface and deep sensors
- Surface imaging
- AI for automated diagnosis and disease scoring




## CONSUMER CARE

Devices and Apps

### Wearable systems

- Environmental, surface, and deep sensors
- Surface imaging
- AI for disease diagnosis, predictions, and recommendations



### Virtual clinical trials

- Environmental, surface, and deep sensors
- Surface imaging
- AI for disease scoring and tracking

## CLINICAL APPLICATIONS

Hospitals and Specialist Outpatient Clinics

### Hyperpersonalised monitoring of diseases

- Environmental, surface, and deep sensors
- Surface, structural, and biochemical imaging
- AI for disease scoring and monitoring

### Personalised therapies

- Surface and deep sensors (biomarkers)
- Surface, structural and biochemical imaging
- AI for disease scoring and personalisation of therapies



CONFIDENTIAL







# Acknowledgements

## Lab of Bio-Optical Imaging (LBOI), Singapore Bioimaging Consortium (SBIC), A\*STAR

- Dr. Chris Ho Jun Hui
- Dr. Xiuting Li
- Ms. Hann Qian Lim
- Prof. Malini Olivo

## Technical University of Munich

- Prof. Daniel Razansky



## Nanyang Technological University

- Prof Adams Kong
- A/Prof Lin zhiping

## National Skin Centre, Singapore

- Dr. Sai Yee Chuah
- Dr Tan Wee Ping



## iThera Medical GmbH, Munich, Germany

- Dr. Neal Burton



- University of Modena
- Prof Pellacani Giovanni.



# Questions and Comments

